What is Oragenics's earnings per share (EPS)?

Oragenics (OGEN) reported diluted earnings per share of $-4.56 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Oragenics Financials

OGEN

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Oragenics (OGEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OGEN FY2025 2026-05-08

Oragenics is operating as a capital-funded development company, with cash burn reshaping the balance sheet more than revenue.

From FY2024 to FY2025, equity swung from negative to positive and cash rose to $4.4M, but that repair came from $16.8M of financing inflow while operations consumed -$9.2M; the stronger balance sheet reflects fresh capital rather than a self-funding operating model.

The loss is now translating into cash burn: FY2025 net loss of -$9.8M was close to operating cash outflow of -$9.2M, so the deficit is economically real rather than mainly non-cash accounting noise. Even with only $1.8M of liabilities on $10.1M of assets, year-end cash of $4.4M covered less than one year of that burn rate, which separates low leverage from true self-funding capacity.

The cost base has shifted away from development: research spending fell from $15.5M in FY2023 to $2.4M in FY2025, while SG&A rose from $5.5M to $7.0M. That means recent cash needs are tied more to keeping the corporate platform running than to scaling experimental work, a meaningful change in how losses are being generated.

Financial Health Signals

Financial Profile 23/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Oragenics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Oragenics carries a low D/E ratio of 0.22, meaning only $0.22 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Returns

Oragenics generates a -11.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Piotroski F-Score Weak

1/9

Oragenics passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

9.39x

For every $1 of reported earnings, Oragenics generates $9.39 in operating cash flow (-$9.2M OCF vs -$984K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-11.9x

Oragenics earns $-11.9 in operating income for every $1 of interest expense (-$9.4M vs $786K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$984K

YoY+6.9%

Oragenics reported -$984K in net income in fiscal year 2025. This represents an increase of 6.9% from the prior year.

EPS (Diluted)

$-4.56

Oragenics earned $-4.56 per diluted share (EPS) in fiscal year 2025. This represents an increase of 90.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$4.4M

YoY+408.7%

5Y CAGR-24.2%

10Y CAGR-1.4%

Oragenics held $4.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Oragenics had 4M shares outstanding in fiscal year 2025. This represents an increase of 919.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-11.9%

5Y CAGR+145.0pp

10Y CAGR+235.7pp

Oragenics's ROE was -11.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$2.4M

YoY-41.8%

5Y CAGR-35.9%

10Y CAGR-12.1%

Oragenics invested $2.4M in research and development in fiscal year 2025. This represents a decrease of 41.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

OGEN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$38K-71.4%	$132K+51.2%	$87K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.4M-41.8%	$4.1M-73.4%	$15.5M+53.8%	$10.1M-4.9%	$10.6M-52.1%	$22.1M
SG&A Expenses	$7.0M+8.2%	$6.4M+18.2%	$5.5M+21.7%	$4.5M-15.0%	$5.3M+16.3%	$4.5M
Operating Income	-$9.4M	N/A	-$20.9M-45.0%	-$14.4M+8.6%	-$15.8M+40.8%	-$26.6M
Interest Expense	$786K+2534.9%	$30K-2.5%	$31K+102.5%	$15K-4.1%	$16K+47.5%	$11K
Income Tax	-$137K	N/A	N/A	N/A	N/A	N/A
Net Income	-$984K+6.9%	-$1.1M+94.9%	-$20.7M-44.6%	-$14.3M+9.1%	-$15.7M+40.6%	-$26.4M
EPS (Diluted)	$-4.56	$-47.88	$-9.18-29.1%	$-7.11	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$645K	N/A	$931K+107.0%	$450K+31.7%	$342K	N/A	$879K-3.1%	$907K
SG&A Expenses	$1.6M	N/A	$2.2M+73.4%	$1.3M-24.9%	$1.7M	N/A	$1.6M+11.4%	$1.4M
Operating Income	-$2.3M	N/A	-$3.1M-82.2%	-$1.7M+15.4%	-$2.0M	N/A	-$2.4M-5.7%	-$2.3M
Interest Expense	$4K	N/A	$7K-98.8%	$572K+187.4%	$199K	N/A	$10K+453.0%	$2K
Income Tax	-$23K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.2M	N/A	-$3.1M-35.0%	-$2.3M-2.5%	-$2.2M	N/A	-$2.5M-6.8%	-$2.3M
EPS (Diluted)	$-0.51	N/A	$-1.96+36.8%	$-3.10	$-3.65	N/A	$-11.32+25.9%	$-15.27

OGEN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$10.1M+583.7%	$1.5M-70.4%	$5.0M-66.3%	$14.8M-47.7%	$28.2M+51.1%	$18.7M
Current Assets	$10.1M+583.7%	$1.5M-61.9%	$3.9M-72.9%	$14.3M-48.4%	$27.7M+54.1%	$18.0M
Cash & Equivalents	$4.4M+408.7%	$865K-75.2%	$3.5M-69.5%	$11.4M-58.1%	$27.3M+54.6%	$17.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8M+6.1%	$1.7M-6.3%	$1.8M+2.8%	$1.7M+0.2%	$1.7M-5.0%	$1.8M
Current Liabilities	N/A	N/A	$1.8M+12.6%	$1.6M+10.4%	$1.4M+7.7%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.3M+4008.4%	-$212K-106.7%	$3.2M-75.6%	$13.0M-50.9%	$26.5M+57.2%	$16.8M
Retained Earnings	-$226.6M-4.5%	-$216.8M-5.1%	-$206.2M-11.1%	-$185.6M-8.3%	-$171.3M-10.9%	-$154.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$7.5M-25.6%	$10.1M-20.8%	$12.7M+493.8%	$2.1M-44.7%	$3.9M+162.8%	$1.5M-71.7%	$5.2M+92.1%	$2.7M
Current Assets	$7.5M-25.6%	$10.1M-20.8%	$12.7M+493.8%	$2.1M-44.7%	$3.9M+162.8%	$1.5M-64.2%	$4.1M+154.1%	$1.6M
Cash & Equivalents	$6.1M+38.8%	$4.4M-61.4%	$11.4M+477.8%	$2.0M-42.3%	$3.4M+295.6%	$865K-72.5%	$3.1M+133.1%	$1.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3M-26.8%	$1.8M-37.8%	$2.9M-32.7%	$4.3M+14.4%	$3.7M+121.5%	$1.7M-20.8%	$2.1M+53.7%	$1.4M
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.2M-25.4%	$8.3M-15.8%	$9.8M+562.1%	-$2.1M-1645.3%	$138K+165.0%	-$212K-106.9%	$3.1M+132.0%	$1.3M
Retained Earnings	-$228.8M-1.0%	-$226.6M-1.0%	-$224.3M-1.4%	-$221.3M-1.0%	-$219.0M-1.0%	-$216.8M-1.6%	-$213.4M-1.2%	-$211.0M

OGEN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$9.2M	N/A	-$7.3M+52.1%	-$15.2M-13.1%	-$13.5M+20.5%	-$17.0M
Capital Expenditures	N/A	N/A	N/A	$128K+190.6%	$44K	N/A
Free Cash Flow	N/A	N/A	N/A	-$15.4M-13.6%	-$13.5M	N/A
Investing Cash Flow	N/A	N/A	-$936K-710.5%	-$116K-163.3%	-$44K	N/A
Financing Cash Flow	$16.8M+180.7%	$6.0M+2006.1%	$284K+157.4%	-$495K-102.1%	$23.1M+41.8%	$16.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.2M+22.4%	-$2.8M+5.0%	-$3.0M-127.1%	-$1.3M+37.8%	-$2.1M-4.6%	-$2.0M-2.4%	-$2.0M-27.6%	-$1.5M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$4.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$92K+45.4%	-$169K-101.4%	$12.4M+9436.8%	-$133K-102.8%	$4.7M+1889.6%	-$261K-106.9%	$3.8M+358.6%	$821K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OGEN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-55519.9%-44555.3pp	-10964.6%+7165.7pp	-18130.3%	N/A
Net Margin	N/A	N/A	-54858.1%-43994.2pp	-10864.0%+7198.1pp	-18062.0%	N/A
Return on Equity	-11.9%	N/A	-652.0%-542.1pp	-109.8%-50.5pp	-59.3%+97.6pp	-156.9%
Return on Assets	-9.8%+62.0pp	-71.8%+344.2pp	-415.9%-319.1pp	-96.8%-41.2pp	-55.6%+85.8pp	-141.5%
Current Ratio	N/A	N/A	2.15-6.8	8.95-10.2	19.17+5.8	13.40
Debt-to-Equity	0.22+8.2	-7.95-8.5	0.57+0.4	0.13+0.1	0.07-0.0	0.11
FCF Margin	N/A	N/A	N/A	-11675.7%+3860.1pp	-15535.8%	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-35.6%	N/A	-31.2%	N/A	-1610.2%	N/A	-80.0%+93.8pp	-173.8%
Return on Assets	-29.4%	N/A	-24.1%+82.0pp	-106.2%-48.9pp	-57.3%	N/A	-47.3%+37.7pp	-85.1%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.210.0	0.22-0.1	0.29+2.3	-2.01-29.1	27.10+35.1	-7.95-8.6	0.69-0.4	1.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Xenetic Biosciences Inc XBIO

$6.7M

GRI Bio GRI

$3.9M

Aptevo Therapeutics Inc APVO

$6.3M

Onconetix ONCO

$1.4M

Quoin Pharmaceuticals Ltd QNRX

$9.7M

Frequently Asked Questions

Is Oragenics profitable?

No, Oragenics (OGEN) reported a net income of -$984K in fiscal year 2025.

What is Oragenics's return on equity (ROE)?

Oragenics (OGEN) has a return on equity of -11.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Oragenics's operating cash flow?

Oragenics (OGEN) generated -$9.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Oragenics's total assets?

Oragenics (OGEN) had $10.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Oragenics spend on research and development?

Oragenics (OGEN) invested $2.4M in research and development during fiscal year 2025.

How many shares does Oragenics have outstanding?

Oragenics (OGEN) had 4M shares outstanding as of fiscal year 2025.

What is Oragenics's debt-to-equity ratio?

Oragenics (OGEN) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Oragenics's return on assets (ROA)?

Oragenics (OGEN) had a return on assets of -9.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Oragenics's cash runway?

Based on fiscal year 2025 data, Oragenics (OGEN) had $4.4M in cash against an annual operating cash burn of $9.2M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Oragenics's Piotroski F-Score?

Oragenics (OGEN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Oragenics's earnings high quality?

Oragenics (OGEN) has an earnings quality ratio of 9.39x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Oragenics cover its interest payments?

Oragenics (OGEN) has an interest coverage ratio of -11.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Oragenics?

Oragenics (OGEN) scores 23 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.